Evidence map›Paper›PMID 41473214›Full record

ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2025

The Effect of Pomegranate Tea on the Clinical Outcomes and Symptom Alleviation in COVID-19 Patients: A Double-Blind Randomized Clinical Trial.

Vahid Reisi-Vanani, Fereidoun Rahmani, Soleiman Kheiri, Akbar Soleimani, Elham Bijad, Zohreh Abolhansanzadeh, Fatemeh Jamshidi-Kia, Zahra Lorigooini

Abstract read
In one paragraph

Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Effect of Pomegranate Tea on the Clinical Outcomes and Symptom Alleviation in COVID-19 Patients: A Double-Blind Randomized Clinical Trial.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vahid Reisi-VananiStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0002-0965-0486
Fereidoun RahmaniDepartment of Infectious Disease, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0001-6929-6573
Soleiman KheiriModeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID https://orcid.org/0000-0001-8285-8681
Akbar SoleimaniDepartment of Internal Medicine, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0002-0763-6285
Elham BijadMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0002-4210-8912
Zohreh AbolhansanzadehMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0002-0709-1174
Fatemeh Jamshidi-KiaDepartment of Horticulture Science, Faculty of Agriculture, Shahrekord University, Shahrekord, Iran, sku.ac.ir.ORCID https://orcid.org/0000-0002-2103-2832
Zahra LorigooiniMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran, skums.ac.ir.ORCID https://orcid.org/0000-0003-0844-7571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19, caused by SARS-CoV-2, emerged as a global pandemic in late 2019, leading to significant health and societal impacts. Treatment challenges have emerged as a result of viral mutations and the strain on healthcare resources, further intensified by the consequences of long-term COVID-19. Recent studies suggest pomegranate ( Methods: This double-blinded randomized clinical trial evaluated the clinical characteristics of hospitalized COVID-19 patients. Pomegranate was sourced and processed into a standardized aqueous extract, with a placebo prepared to match its appearance. Eligible participants with confirmed COVID-19 pneumonia were randomized into intervention and placebo groups based on their respiratory support needs. Both groups received treatment during their hospital stay and continued postdischarge until symptom resolution. Standard treatment protocols were followed for all participants. Results: This double-blinded randomized clinical trial evaluated the clinical characteristics of 66 hospitalized COVID-19 patients. The median age of participants was 56 years, and demographics were similar across groups. Notably, 58.7% had symptom onset within the last 10 days. There were statistically significant differences in baseline laboratory markers or primary outcomes, including hospitalization duration and time to improvement. Secondary outcomes similarly demonstrated no significant differences in mortality, respiratory support duration, severity of clinical symptoms, or adverse effects. Conclusion: This study finds no significant advantage of pomegranate tea in managing COVID-19 but highlights the inherent challenges in researching emerging infectious diseases. Our research highlights the necessity of continuously refining methodologies and adapting to the dynamic nature of emerging pathogens. Such efforts are essential for advancing the search for effective treatments and ultimately enhancing patient care. These findings contribute critically to the ongoing exploration of therapeutic strategies against viral infections, fostering a deeper understanding of potential interventions.

Indexed as

emerging communicable diseasespomegranaterandomized controlled trialSARS-CoV-2

Identifiers

PMID41473214
PMCPMC12747076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.